Severely Active Ulcerative Colitis

PHILADELPHIA — Risankizumab outperformed placebo in endoscopic improvement and remission through 52 weeks of maintenance therapy in moderately to severely active ulcerative colitis, regardless of induction outcomes, according to data.

WASHINGTON — A maintenance dose of subcutaneous Skyrizi may still induce clinical response in patients with ulcerative colitis who failed to achieve response after 12 weeks of IV induction, noted a presenter at Digestive Disease Week.

WASHINGTON — “Even at short intervals,” an intermittent low-calorie, plant-based diet may improve inflammation and response to medical therapy among patients with moderately to severely active ulcerative colitis, according to a presenter.